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The presence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and
the permanent integration of HBV DNA into the host genome confers the risk of viral
reactivation and hepatocellular carcinoma. Nucleoside/nucleotide analogs alone have
little or no capacity to eliminate replicative HBV templates consisting of cccDNA or
integrated HBV DNA. Recently, CRISPR/Cas9 technology has been widely applied
as a promising genome-editing tool, and HBV-specific CRISPR-Cas9 systems were
shown to effectively mediate HBV cccDNA disruption. However, the integrated HBV
DNA fragments are considered as important pro-oncogenic properties and it serves
as an important template for viral replication and expression in stable HBV cell line. In
this study, we completely excised a full-length 3,175-bp integrated HBV DNA fragment
and disrupted HBV cccDNA in a stable HBV cell line. In HBV-excised cell line, the HBV
cccDNA inside cells, supernatant HBV DNA, HBsAg, and HBeAg remained below the
negative critical values for more than 10 months. Besides, by whole genome sequencing,
we analyzed off-target effects and excluded cell contamination. It is the first time that
the HBV infection has been fully eradicated in a stable HBV cell line. These findings
demonstrate that the CRISPR-Cas9 system is a potentially powerful tool capable of
promoting a radical or “sterile” HBV cure.
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INTRODUCTION
Chronic hepatitis B (CHB) is a major public health problem worldwide, with 350–400 million
chronic HBV (hepatitis B virus) carriers (Seo and Yano, 2014). HBV infection results in 0.5–1
million deaths per year due to cirrhosis of the liver, hepatocellular carcinoma, and liver failure
(Kao and Chen, 2002; Roberts and Gores, 2005). HBV covalently closed circular DNA (cccDNA) is
Abbreviations: HBV, hepatitis B virus; NAs, nucleoside/nucleotide analogs; cccDNA, covalently closed circular DNA;
CRISPR, clustered regularly interspaced short palindromic repeat; gRNA, guide RNA; PAM, protospacer adjacent motif;
DSBs, double-strand breaks; HBS, hepatitis B surface antigen; indel, insertion or deletion; SD, standard deviation; NHEJ,
Non-homologous end joining; PSAD, plasmid safe ATP-dependent DNase; RCA, rolling circle amplification.
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very stable in CHB patients and serves as the template for viral
mRNA and pre-genomic RNA synthesis (Moraleda et al., 1997;
Dandri et al., 2000; Gish et al., 2015; Guo and Guo, 2015; Nassal,
2015). The integration of HBV DNA into the host genome can
cause alterations of the host genome, leading to changes in genes
associated with cell proliferation, differentiation, and survival
(Bonilla Guerrero and Roberts, 2005; Feitelson and Lee, 2007;
Jiang S. et al., 2012; Jiang Z. et al., 2012; Sung et al., 2012; Xu
et al., 2014). HBV DNA integration is also an important factor in
hepatocarcinogenesis (Bréchot, 2004; Sung et al., 2012; Tarocchi
et al., 2014; Xu et al., 2014). Current anti-HBV treatments
with either nucleoside/nucleotide analogs (NAs) or interferon
do not cure CHB, and relapses are common (Bang and Kim,
2014). Although NAs can inhibit viral reverse transcriptase
and suppress HBV replication, these drugs alone have little or
no ability to eliminate replicative HBV templates comprising
cccDNA (Moraleda et al., 1997; Dandri et al., 2000) or integrated
HBV DNA (Zucman-Rossi and Laurent-Puig, 2007). Given the
shortcomings of current therapeutic options, there is a need to
approach CHB in a fundamentally different way (Shaw et al.,
2006; Sharon and Chu, 2008).
A new genome-editing tool, CRISPR-Cas9, was recently
developed based on the bacterial immune system’s clustered
regularly interspaced short palindromic repeats (CRISPRs) (Qi
et al., 2013). Zinc Finger Nucleases (ZFNs) and Transcription
activator-like effectors nucleases (TALENs) have been under
investigation for their capacity to specifically disrupt HBV
genomes in vitro and in vivo (Cradick et al., 2010; Bloom
et al., 2013; Chen et al., 2014). However, compared with ZFNs
and TALENs, the CRISPR/Cas9 system can be more easily
reprogrammed and delivered both in vitro and in vivo to
cleave virtually any DNA sequence by simply redesigning the
guide RNAs (gRNAs), which is predicated to be a promising
genome-editing tool with broad applications (Qi et al., 2013; Ran
et al., 2013; Zhang et al., 2014). Using CRISPR-Cas9, Hu et al.
completely excised the full length of integrated HIV proviral
DNA in a stable HIV monoclonal cell line (Hu et al., 2014).
In these studies, HBV-specific CRISPR-Cas9 systems effectively
mediated gene disruption inHBV templates in expression vectors
(Lin et al., 2014; Liu et al., 2015) and HBV cccDNA (Seeger
and Sohn, 2014; Kennedy et al., 2015; Zhen et al., 2015a) both
in vitro and in vivo. However, none of these studies demonstrated
removal of the full-length integrated HBV DNA and subgenomic
integrated HBV DNA fragments in a stable HBV cell line (Lin
et al., 2014; Seeger and Sohn, 2014; Kennedy et al., 2015; Liu
et al., 2015; Zhen et al., 2015a). These shortcomings largely
limited the prospect of developing a fundamental therapeutic
method of viral eradication through CRISPR-Cas9. Several
studies have proposed that removal of integrated HBV DNA
from the host genome is a necessary measure to recover the
stability of the chromosome and cure HBV-related HCC (Peng
et al., 2015; Ramanan et al., 2015; Wang et al., 2015). In a
pioneering study, Karimova et al. disrupted integrated HBV
DNA, using an integrated HBV reporter sequence in HeLa and
HEK293 cell lines (Karimova et al., 2015). In HBV-infected
cells, the existence of many different forms of episomal HBV
DNA (Tuttleman et al., 1986) and multiple integrated HBV
sites in different chromosomes (Matsubara and Tokino, 1990)
made it cumbersome to specifically amplify the full length of
integrated HBV DNA sites in a stable HBV cell line, using
Alu-/LM-PCR. Also, the limitations of the short reads generated
by next-generation sequencing (NGS) meant that HBV DNA
integration sites could only be inferred from paired-end reads
containing both human and viral sequences (Hai et al., 2014). In a
previous study, we established a stable HBV cell line, HepG2.A64
(CCTCC C 201163), using genotype C HBV strains (GenBank:
HQ638218.1) isolated from hepatitis B patients (Wei-ming et al.,
2014). Compared with HepG2.2.15, this cell line could produce
more antigens, virions, and HBV cccDNA, and was easier to
cultivate and transfect. HBV transfected in HepG2.A64 cells
contained entecavir-resistant mutations, which had already been
used in drug resistance investigations (Liu et al., 2016). Moreover,
we employed CRISPR-Cas9 to disrupt HBV cccDNA and inhibit
viral replication in this cell line in our previous study (Li et al.,
2016). In this study, not only HBV cccDNA, we also removed
the full length of integrated HBV DNA, which means that we
achieved a “sterile” eradication of HBV infection in this stable
HBV cell line.
MATERIALS AND METHODS
Plasmid Preparation
The Cas9/gRNA dual-expression vector pSpCas9(BB)-2A-Puro
(PX459) was a gift from Feng Zhang (Addgene plasmid #48139)
and was constructed according to a previously described protocol
(Ran et al., 2013). Using a gRNA prediction tool (http://crispr.
mit.edu/), five candidate target sequences were derived from the
HBV genome (GenBank accession number HQ638218). These
protospacers were subsequently inserted into dual-expression
vectors under the control of the U6 promoter. Plasmids
were purified using the EndoFree Plasmid Maxi Kit (Qiagen,
Germany).
Cell Culture and Transfections
All cells were maintained in Dulbecco’s modified Eagle medium
supplemented with 10% fetal calf serum at 37◦C and 5% CO2.
The HepG2.A64 (CCTCC C 201163) monoclonal cell line was
established from HepG2 cells transfected with an HBV plasmid
pTriexHBV1.1 containing 1.1 copies of HBV DNA (GenBank:
HQ638218.1) (Wei-ming et al., 2014). This monoclonal cell
line sustainably produced HBsAg, HBeAg, and HBV DNA. A
total of 2 × 106 A64 cells were seeded onto 10-cm plates 24
h before transfection. The Cas9/gRNA co-expression vectors
were transfected into A64 cells using Lipofectamine LTX (Life
Technologies, US). Puromycin (1µg/µl) was used to increase
transfection efficiency (Figure S1). At 72 h after transfection,
transfected cells were seeded onto 24-well-plates (∼4 × 104 cells
per well) for subsequent analysis. For subcloning, stable clones
were subcultured after transfection and underwent puromycin
selection by a limiting dilution method in 96-well-plates,
and single cell-derived subclones were maintained for further
studies.
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T7EI Assay
The genomic region surrounding the target regions A and B
was amplified by PCR; specific primers were designed with
primer premier 5.0 (Table S1). All PCR products were verified
by Sanger sequencing and subjected to a re-annealing process
to induce heteroduplex formation. After re-annealing, products
were treated with T7EI (New England Biolabs, US) at 37◦C for 30
min and analyzed using 3% agarose gels. Gels were imaged using
a gel imaging system (Bio-Rad, US).
Immunoassay and qPCR
HBsAg and HBeAg were measured in the cell supernatants,
using an ARCHITECT i2000 SR system (Abbott, US); data were
reported in IU/ml for HBsAg and S/CO for HBeAg. Cell culture
supernatants were extracted and tested for the presence of HBV
DNA by real-time PCR. To quantitate HBV cccDNA, circular
duplex DNA was subjected to PlasmidSafe ATP-dependent
DNase (Epicentre, US), which has low activity toward HBV
rcDNA, dsDNA, and ssDNA. Rolling circle amplification (RCA)
was then performed to selectively amplify circular DNA. Based on
the RCA products, HBV cccDNA was amplified and quantitated
by TaqMan real-time PCR using specific cccDNA-selective
primers and a probe targeting the gap region between DR1 and
DR2 of the HBV genome (Zhong et al., 2011). To detect genomic
DNA contamination, primer sets that amplify the HBV S DNA
or control cellular genomic sequences located in the A1AT gene
were used (Table S1). To quantitate the cell number, specific
primers for human β-actin were used for real-time PCR.
Whole-Genome Sequencing and
Bioinformatics Analysis
Genomic DNA was isolated by a cetyltrimethylammonium
bromide (CTAB)-based extraction method. DNA samples and
genomic DNA libraries were prepared by the NGS facility at the
Biomarker Technologies Company. All libraries were sequenced
with paired-end 150-bp reads in two Illumina Rapid Run flow
cells, using a HiSeq X 10 instrument (Illumina). Demultiplexed
read data from the sequenced libraries were sent to the Biomarker
Technologies Company for bioinformatics analysis. Briefly, the
raw reads were mapped against the human genome (hg19), using
BWA. A genomic analysis toolkit (GATK, version 2.8.1) was
used for removal of duplicate reads, local alignment, base quality
recalibration, and indel calling.
Statistical Analysis
For statistical analysis, Student’s t-test was performed using the
SAS software suite. P < 0.05 was considered significant. Error
bars represent the SEMof at least three independent experiments.
RESULTS
Analysis of Integrated HBV DNA and
Rationale for Selection of the
CRISPR-Cas9 Target Site
We used the stable HBV cell line HepG2.A64 (CCTCC C 201163,
hereafter referred to as “A64”) as a cell model. The full length
of integrated HBV DNA in this cell line was dependent on a
foreign promoter (CMV chicken β-actin promoter) instead of
viral promoters, which enabled amplification of the full-length
replication-competent integrated HBV DNA, using a specific
primer (P1) located in the foreign promoter region (Figure 1A).
To ensure that the PCR products of the primers (P1 and P2)
were the integrated HBV DNA rather than the fragment on
pTriexHBV1.1, we used Plasmid-Safe ATP-Dependent DNase
(PSAD) to extract the circular duplex DNA. HBV-specific
primers (HBSF&R) and genome-specific primers (A1ATF&R)
were used as the positive and negative controls, respectively, to
evaluate the effect of the circular duplex DNA on extraction.
The P1 primer and the HBV S gene-specific primer P3 did
not amplify the circular duplex DNA (Figures 1C,D), indicating
that there was no circular pTriexHBV1.1 in the stable HBV cell
line A64 and that primer P1 was an integrated HBV DNA-
specific primer. Next, we performed long-range PCR, using A64
genomic DNA with integrated HBV DNA-specific primers (P1
and P2) with a Phusion High-Fidelity PCR Kit (NEB, US),
following the manufacturer’s protocol. Sequencing of the PCR
products revealed a 4,049-bp DNA fragment representing the
3,362-bp integrated HBV DNA (1.1 copies) plus a flanking 687-
bp pTriexHBV1.1-derived sequence (Figure 1B). The 3,362-bp
integrated HBVDNA contained an entire 3,173-bp HBV genome
and a 189-bp repeat sequence of the HBV core region. To remove
the full-length integrated HBV DNA, we employed one gRNA
targeting the two repeat regions of the integrated HBV DNA,
which was expected to be more efficient in transfection and have
lower off-target potential than the use of two gRNAs (Figure 1A).
By online efficiency prediction (Hsu et al., 2013; Mali et al., 2013),
we identified five gRNA targets with fewer off-target effects on
the host genome (Table S2) and constructed the corresponding
CRISPR-Cas9 systems.
Specific Inactivation of HBV Replication by
CRISPR-Cas9
To assess the capacity to generate apparent cleavage at both
ends of the integrated HBV DNA, we performed a mismatch-
sensitive T7 endonuclease I (T7EI) assay (Ran et al., 2013)
after transfecting the five gRNAs into the A64 cell line
(Figure 2A). All of the systems introduced double-strand breaks
(DSBs) into both ends of the integrated HBV DNA, but
gRNA-69 was the most efficient system (Figure 2A). Next, to
determine the knockout efficiency of the gRNAs in A64 cells,
we used an ARCHITECT HBsAg and HBeAg reagent kit to
determine the amounts of HBeAg and HBsAg in the cell culture
supernatants on 16 consecutive days post-transfection. At day
9 after transfection, compared with that in the gRNA-empty
group, HBeAg concentrations were reduced 83.13 ± 0.14% in
the gRNA-91-treated group, 80.53 ± 2.43% in the gRNA-69-
treated group, 70.71 ± 2.09% in the gRNA-62-treated group,
and 76.50 ± 0.27% in the gRNA-60-treated group. HBsAg
concentrations were reduced 87.38 ± 1.56% in the gRNA-91-
treated group, 86.49 ± 1.79% in the gRNA-69-treated group,
80.07± 1.01% in the gRNA-62-treated group, and 82.55± 0.78%
in the gRNA-60-treated group. HBV DNA concentrations
were reduced 91.72 ± 1.55% in the gRNA-91-treated group,
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3 March 2017 | Volume 7 | Article 91
Li et al. Eradication of HBV by CRISPR-Cas9
FIGURE 1 | Analysis of integrated HBV DNA in the stable HBV cell line A64. (A) Integrated HBV DNA in the stable HBV A64 cell line and the gRNA target sites
in the repeat region of the 1.1 HBV genome copy. (B) The 4,049-bp DNA fragment representing the 3,362-bp integrated HBV DNA (1.1 copies) plus a 687-bp
pTriexHBV1.1-derived flanking sequence was efficiently amplified from cellular genomic DNA using the integrated HBV-specific primers P1 and P2. (C) PCR analysis
using the A1AT and HBV S-gene primer sets conducted on total genomic DNA and circular duplex DNA to assess the effect of extraction on circular duplex DNA.
(D) PCR analysis of the integrated HBV DNA or circular duplex DNA isolated from cells using the P1/P3 and S-gene primer sets. Using P1 and the HBV core
region-specific primer P3, the HBV S-gene amplicons were predicted to be 542- and 572-bp, respectively. Primers P1/P3 did not amplify circular duplex DNA.
FIGURE 2 | Inhibition of both HBV antigen expression and HBV replication by CRISPR-Cas9 in A64 cells after transfection. (A) DNA extracted from A64
cells transfected with gRNA-91, gRNA-69, gRNA-65, gRNA-62, and gRNA-60 was analyzed by a T7EI assay. Predicted sizes of uncut and cut bands are indicated.
(B–D) Inhibition of HBsAg, HBV DNA, and HBeAg in cell culture supernatants at the indicated time points after transfection of A64 cells with gRNA-91, gRNA-69,
gRNA-65, gRNA-62, and gRNA-60.
89.21 ± 2.72% in the gRNA-69-treated group, 80.30 ± 1.30% in
the gRNA-62-treated group, and 86.95 ± 1.93% in the gRNA-60
treated-group. It is noteworthy that the suppression of HBsAg
and HBV DNA was slightly higher than that of HBeAg. During
16 consecutive days after transfection, HBV DNA, HBeAg,
and HBsAg concentrations in culture supernatants were low
in the gRNA-91, gRNA-69, gRNA-62, and gRNA-60 groups
(Figures 2B,D) compared with those in the gRNA-empty group
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(Figure 2C). Neither the HBVDNA nor HBV antigens have been
reduced in the cells transfected with gRNA-65. Moreover, at 10
and 14 day post-transfection, the entire group showed a drop-off
in suppression of HBeAg and HBV DNA. This phenomenon was
expected due to the loss cells during medium changing.
CRISPR-Cas9 Excised the Full-Length
Integrated HBV Genome and Disrupted
HBV cccDNA
We expected that expression of the gRNAs in A64 cells would
result in the deletion of the entire 3,173-bp HBV genome
between the A and B target sites. By long-range PCR analysis,
we found one subclone, HepG2.A64-69-7 (A64 transfected with
gRNA-69, hereafter referred to as “69-7”), which contained a
complete deletion of the entire 3,173-bp integrated HBV genome
(Figure 3A). An 873-bp fragment representing the predicted
segment resulting from its flanking region was amplified
(Figure 3A), suggesting gRNA-69 enabled Cas9 to excise the
full-length integrated HBV genome segment. Sequence analysis
demonstrated that the 873-bp fragment included 687-bp from
the integrated pTriexHBV1.1-derived flanking sequence and a
186-bp HBV repeat core region sequence, with a 3-bp deletion
at the gRNA-69 target site, which was expected to result from
gRNA-69-guided cleavage and repair (Figure 3B).
Next, we performed quantitative analysis of HBsAg and
HBeAg in the supernatant (Figures S1A,B) and real-time
PCR analysis of supernatant HBV DNA and HBV cccDNA
(Figures S1C,D). The HBV DNA in the supernatant from the
gRNA-empty-treated group (subclone K-15) had a concentration
of 775,033± 29,868 IU/ml at day 10 after continuous cultivation,
whereas the concentration of the HBV DNA in the supernatant
FIGURE 3 | CRISPR-Cas9/gRNA-69 efficiently removed the integrated HBV genome from a stable HBV cell line. (A) Analysis of PCR amplicon lengths
using a primer pair (P1 and P2) targeting the integrated HBV-flanking sequence revealed elimination of the full-length integrated HBV genome (3,173-bp), leaving one
fragment (873-bp predicted segment from its flanking region). (B) Diagram showing excision of the full-length integrated HBV genome. The remaining fragment
included the expected 687-bp from the integrated HBV flanking sequence and a 186-bp HBV repeat core region sequence. (C) Sanger sequencing of the remaining
fragment (873-bp) showing the HBV flanking sequence (small letters, 687-bp) and the partial sequences (189 − 3 = 186-bp) of the integrated HBV repeat region B
(green) and repeat region A (red) with a 3-bp deletion around the gRNA-69 targeting site (yellow-highlighted). Elimination of the full-length integrated HBV genome is
indicated by a strikethrough. (D,E) The amounts of HBeAg, HBsAg and HBV DNA in cell culture supernatants and HBV cccDNA in the gRNA-empty-treated group
(K-15) and gRNA-69-treated group (69-7) over 300 consecutive days. The HBsAg and HBeAg test results in the gRNA-69-treated group (69-7) were always under the
negative threshold (0.05 IU/ml for HBsAg and 1 S/CO for HBeAg), and the amounts of HBV DNA and HBV cccDNA in the supernatants were always undetectable (<
500 IU/ml for qPCR) in the gRNA-69-treated group (69-7). All viral markers in the gRNA-empty-treated group (K-15) remained at high levels.
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from the gRNA-69-treated group (subclone 69-7) was 420 ± 278
IU/ml. HBV cccDNA in subclone 69-7 was undetectable by qPCR
(<500 copies/106 cells), whereas HBV cccDNA in subclone K-
15 had a concentration of 11,807,834 ± 3,431,702 copies/106
cells (Figures S1C,D). Additionally, the amounts of HBsAg and
HBeAg in the supernatant from subclone 69-7 were always below
the negative threshold (0.05 IU/ml for HBsAg and 1 S/CO for
HBeAg) for 10 consecutive days, whereas the amounts of HBsAg
and HBeAg in the supernatant from subclone K-15 increased
rapidly (Figures S1A,B). Next, to test whether this HBV clearance
could be repaired, we conducted long-term observations of
subclones 69-7 and K-15. In contrast to the high levels of HBeAg
and HBsAg in the supernatant from subclone K-15, the amounts
of HBeAg, HBsAg, and HBV DNA in the supernatant from
subclone 69-7 remained below the negative critical values for 300
consecutive days; additionally, HBV cccDNA was undetectable
in subclone 69-7. In contrast, all of these viral markers remained
high in subclone K-15 for 300 consecutive days (Figures 3D,E).
Whole Genome Sequencing of
HBV-Excised Cell Line
To assess possible off-target effects of CRISPR-Cas9 and the
integrated subgenomic HBV DNA fragments in the original
HBV-containing cell line (A64) and HBV-excised cell line (69-7),
whole-genome sequencing (WGS) was performed. The average
coverage was 71 folds in A64 and 67 folds in 69-7. In total,
with human (GRCh37/hg19) genomes as reference sequences,
we identified 4,981,628 SNPs, 914,579 indels and 24,344 SVs
in A64 cells and 3,834,414 SNPs, 771,687 indels, and 16,719
SVs in 69-7 cells using GATK, v.2.8.1. Next, we performed an
analysis of±500-bp flanking each indel against predicted gRNA-
69 off-target sites (Table S3). In total, we identified 6 indels in
50 potential off-target regions (Table 1), while four indels were
identified in two cell lines and only two indels were different
after gRNA-69 transfection, which suggests that gRNA-69 did
not have significant off-target indels. Moreover, after comparing
the SNPs and indels between HepG2.A64.69-7 and HepG2.A64
cells, we found that 1,175,423 SNPs and 154,931 indels were only
present in the stable HBV cell line and not the HBV-excised
cell line; 28,209 SNPs and 12,039 indels were present only in
the HBV-excised cell line but not in the stable HBV cell line;
3,806,205 SNPs and 759,648 indels occurred in both samples.
Thus, it means that the HBV-excised HepG2.A64.69-7 cell line
missed millions of mutations compared with the stable HBV cell
line HepG2.A64.
As a proof that the HBV-excised monoclone 69-7 did not
exist in a very small amount as contaminants in the stable
HBV cell line A64 before gRNA-69 treatment, we found a
specific residual sequence of gRNA-69/Cas9 cleavage (Figure 4),
which confirmed that this monoclone was generated by gRNA-
69/Cas9. Sanger sequencing of PCR products containing the
excision site (Figure 3C) showed that after full-length HBVDNA
excision by gRNA-69/Cas9 and non-homologous end joining
(NHEJ) repair, three extra nucleotides “GAA” were deleted at the
gRNA-69 cleavage site located in the HBV C region. Thus, we
searched two 20-bp sequences (CCCGTATAAATTTGGAGCTT
and CCGTATAAAGAATTTGGAGC) that could distinguish the
original and excised DNA in the raw sequencing data (coverage
60×) of the two samples. The results showed that before gRNA-
69/Cas9 transfection, we could not find the residual sequence
with the “GAA” deletion in the stable HBV cell line A64, while 11
reads containing the residual sequence with the “GAA” deletion
were found in the 69-7 sequencing data. This residual sequence
with the “GAA” deletion at the gRNA-69 targeting region not
only indicated that the HBV-excised cell line was established by
gRNA-69/Cas9, it also verified that this monoclone was not a
contaminated clone in the A64 cell line.
DISCUSSION
CRISPR-Cas9 represents a potential means to radically cure
chronic viral infections because this system was demonstrated to
disrupt HBV cccDNA with favorable effects (Seeger and Sohn,
2014; Kennedy et al., 2015; Zhen et al., 2015a). Seeger et al.
demonstrated that the use of CRISPR/Cas9 is currently the best
method of functionally inactivating HBV cccDNA (Seeger and
Sohn, 2016). HBV infection can induce HBV DNA fragment
integration into the host genome, which had been observed in
∼80% of cases of HBV-induced hepatocarcinogenesis (Bréchot,
2004; Hai et al., 2014). Integrated HBV DNA could lead to
aberrant regulation of host gene expression (Jiang S. et al., 2012;
Jiang Z. et al., 2012; Sung et al., 2012; Xu et al., 2014) and
higher genomic instability (Cha and Dematteo, 2005). Many
HBV integration events occurred near or within fragile sites and
other repetitive regions, such as TERT, FN1, MLL4, ROCK1,
CCNE1, SENP5 (Jiang Z. et al., 2012; Sung et al., 2012; Hai et al.,
TABLE 1 | Detailed information on six called indels near gRNA-69 predicted off-target sites in A64 and 69-7 cells.
Name gRNA-target Indels Genotype
Chromosome Position Strand Chromosome Position Reference Quality Mutation gRNA-empty gRNA-69
gRNA-69 18 76,276,328 + 18 76,276,322 T 4109.16 TC 1/1 1/1
gRNA-69 9 114,763,107 − 9 114,763,025 C 785.4 CTGA 0/1 0/1
gRNA-69 13 68,377,461 + 13 68,377,761 A 655.4 AT 0/1 0/1
gRNA-69 6 152,925,354 − 6 152,925,295 A 543.19 ATG 1/1 0/0
gRNA-69 15 96,449,419 + 15 96449337 A 3684.15 AAAAAG 0/1 1/1
gRNA-69 2 68,269,754 + 2 68,269,960 CGGGGGGGG 2285.21 C 1/1 1/1
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FIGURE 4 | Sanger sequencing of the gRNA-69/Cas9 target region both in the HBV-excised cell line 69-7 (upper half) and two ends of the full-length
integrated HBV DNA in the stable HBV cell line A64 (lower half). The specific residual sequence with a three-nucleotide “GAA” deletion at the gRNA-69/Cas9
cleavage region in HBV-excised cell line 69-7 was used to distinguish it from the stable HBV cell line. The extra “GAA” deletion was marked by a red line in the stable
HBV cell line A64.
2014), Alu sequences, and microsatellites, which are prone to
tumor development and progression (Feitelson and Lee, 2007).
Gounder et al. demonstrated that the reduced risk of HCC was
not associated with HBsAg seroclearance, and speculated that it
was probably associated with the existence of HBV cccDNA and
integrated HBV DNA (Gounder et al., 2016). Here, as proof of
concept, we employed the CRISPR-Cas9 system to eradicate HBV
infection and eliminated the persistent HBV genome, including
the full-length integrated HBV DNA and HBV cccDNA, in a
stable HBV cell line. These findings indicated that CRISPR-
Cas9 could not only provide a powerful path toward a radical
or “sterile” HBV cure, but also provide a means of blocking
carcinogenesis by eliminating HBV cccDNA and integrated
HBV DNA.
Using gRNAs targeting the HBV core region, the level of
HBsAg and HBV DNA was reduced by an equal level as that
of HBeAg (Figures 2B–D). It had been considered as a global
reduction in cccDNA in this case (Seeger and Sohn, 2014;
Kennedy et al., 2015; Zhen et al., 2015b) for the HBV cccDNA
rapid cleavage efficiency, resulting in a high percentage of linear
DNAs that is not repaired but rather destroyed (Dong et al.,
2015). However, the inhibitory effect on gRNA-directly targeted
genes was stronger than the effect on other HBV antigens in
previous studies (Lin et al., 2014; Kennedy et al., 2015). Since the
functional full-length integrated HBV DNA is also a replication
root in an HBV-transgenic cell model (Sells et al., 1987) and
these four effective gRNAs targeted both ends of the full-length
integrated HBV DNA, we reasoned that this more thorough
clearance of HBV expression was not only caused by the global
reduction of cccDNA, but also by the removal of the full-length
integrated HBV DNA. Another possible reason for this overall
reduction was that the region we targeted, which contained
the viral enhancer, X gene, and core gene(Sung et al., 2012),
is essential for HBV replication or even integration (Zoulim
and Locarnini, 2009). Since the specific mechanisms of HBV
replication and integration remain controversial, we expect that
this region will be an area of focus for future research.
In amonoclone of the stable HBV cell line 69-7, the full-length
integrated HBV genome was excised. It is the first time, to our
knowledge, that the HBV infection in a stable HBV cell line was
removed thoroughly and completely using CRISPR-Cas9. At first,
we aimed to value the off-target effect of gRNA-69. Unexpectedly,
after sequencing the whole genome, we identified 4,981,628 SNPs
in HepG2.A64 cells and only 3,834,414 SNPs were detected in
the HBV-excised 69-7 cell line. We found that 1,175,423 SNPs
in HepG2.A64 were absent after HBV excision. There may be
two possibilities to explain this finding. Firstly, those abundant
missing SNPs may be due to limited WGS coverage. Secondly, as
many studies have demonstrated that HBV proteins such as HBx,
HBsAg and core proteins could interfere with DNA repair [i.e.,
the NER (Jaitovich-Groisman et al., 2001; Lieber, 2010), BER (van
de Klundert et al., 2012) or ATR (Rakotomalala et al., 2008;Wang
et al., 2008)] pathways, this could have exacerbated DNA damage,
by interfering with checkpoint activation, promoting cell cycle
progression and ultimately leading to genetic aberrations. We
speculate that those missing SNPs could have been eliminated by
the re-activated DNA repair mechanism of the host. However, the
specific mechanisms of HBV integration and HBV pathogenesis
remain controversial, and this suggestion still needs further
research.
In addition, as we established only one HBV-excised subclone
without any HBV replication markers and missing abundant
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SNPs, there is a possibility that this HBV-excised subclone we
selected is just the HepG2 cell line contaminated in HepG2.A64.
To rule out this possibility, we used the WGS results with
a specific residual sequence of the gRNA-69/Cas9 cleavage to
evaluate the contaminant. The results showed that the HBV-
excised monoclone 69-7 did not exist as contaminants in the
stable HBV cell line A64 before transfection and it was generated
by gRNA-69/Cas9. Unlike previous studies using CRISPR-Cas9
to disrupt HBV, we not only disrupted HBV cccDNA but also
swept the full-length of integrated HBV DNA in the stable
HBV cell line. In the HBV-excised cell line 69-7, HBV cccDNA,
supernatant HBV DNA, HBsAg, or HBsAg could not be detected
for 10 consecutive months. This showed that once the root of
HBV replication in a stable HBV cell line had been eradicated,
and HBV infection was persistently undetectable without any
treatment. As the development of the next generation of
sequencing technology, we could specific locate the integrated
HBV DNA fragments. The developed online gRNA predicting
tool could be used to design gRNAs with less off-target effect.
Besides, in recent years, Adeno-Associated Virus Vectors (AAV)
has captured much attention as a gene delivery system for
treating human disease caused by a gene loss or mutation.
The advantages of the AAV delivery scheme include its low
toxicity and sustained gene expression, which can extend to 12
months after a single administration. Those properties mean that
completely eradication of HBV infection in clinical CHB patients
will be achieved in the near future.
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